A drug and device company, EpicentRx has developed two complementary therapeutic platforms, CyNRGY and AdAPT, that each target the common cause of most, if not all diseases, including cancer, which is inflammation, as well as specialized devices to deliver these therapies.
EpicentRx’s first clinical stage product with the CyNRGY platform, RRx-001, has been tested in several clinical trials including an ongoing Phase 3 study in small cell lung cancer. It is among a portfolio of first-in-class small molecule compounds that favorably alter the tumor microenvironment, down-regulating CD47 and activating tumor associated macrophages (TAMs). In addition, these small molecules have demonstrated anti-inflammatory and normal tissue-protective properties, through their effect on Nrf2 and the inflammasome, which render them potentially active against a whole host of inflammatory, iatrogenic and autoimmune diseases in and outside of cancer including oral and intestinal mucositis, Acute Radiation Syndrome (ARS), chemical weapons, Alzheimer’s, Crohn’s, gout, congestive heart failure, macular degeneration, glomerulonephritis, ALS, Parkinson’s, diabetes and multiple sclerosis.
The company is also advancing multiple products through its AdAPT platform, built around a next generation viral vector (TAV-255), and highlighted by the clinical stage AdAPT-001, designed to selectively infect and draw an immune response, turning them from cold to hot, and making them susceptible to other therapies such as checkpoint inhibitors. In addition TAV-255 is used as the backbone for the development of next generation personalized cancer vaccines to amplify cancer-specific T cell responses through overexpression of tumor neoantigens.